03-05-2025
Lemaitre Vascular (LMAT) Receives a Buy from Roth MKM
In a report released today, Jason Wittes from Roth MKM maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report), with a price target of $106.00. The company's shares closed today at $78.70.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Wittes is a 3-star analyst with an average return of 2.3% and a 46.18% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Accuray, Globus Medical, and Allurion Technologies.
Lemaitre Vascular has an analyst consensus of Moderate Buy, with a price target consensus of $107.29, implying a 36.33% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $115.00 price target.
The company has a one-year high of $109.58 and a one-year low of $69.82. Currently, Lemaitre Vascular has an average volume of 225.9K.
Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LMAT in relation to earlier this year. Most recently, in March 2025, Trent Kamke, the Senior V. P., Operations of LMAT sold 6,529.00 shares for a total of $525,015.67.
